2019 BACR Special Conference on Breast Cancer hosted by Breast Cancer Now

New Developments in Breast Cancer Research – From the Lab to the Clinic

The Sage, Newcastle Gateshead, October 9th-11th 2019

Organisers: Rob Clarke, Ingunn Holen, James Flanagan, Val Speirs

PROGRAMME

Day 1

12.00-12.45	**Arrival and registration, lunch**
12.45-13.00	Welcome and intro (Delyth Morgan)
Session 1	**The Changing Landscape of Breast Cancer** **Chaired by: Rob Clarke (University of Manchester)**
13.00-13.45	Scientific Keynote: Breast tumour heterogeneity: Act locally, think globally – Momo Bentires-Alj (University of Basel, Switzerland)
	Short communications from selected abstracts
13.45-14.00	BCL11A enables aberrant differentiation of TNBC tumour initiating cells - Walid Khaled (University of Cambridge)
14.00-14.15	Use of an ex vivo breast cancer patient-derived explant platform to evaluate biomarkers for novel anti-cancer drugs - Constantinos Demetriou (University of Leicester)
14.15-14.30	Targeting therapy-induced senescence to limit breast cancer metastasis - Douglas Perkins (Institute of Cancer Research, London)
14.30-15.00	**Coffee break**
Session 2	**Immunotherapy – use in breast cancer treatment and model systems** **Chaired by: Momo Bentires-Alj (University of Basel, Switzerland)**
15.00-15.30	Immune Complexity of Metastatic Breast Cancer: towards personalized immune intervention strategies. Karin de Visser (Netherlands Cancer Institute, The Netherlands)
15.30-16.00	Immunotherapy in breast cancer – where are we? Anne Armstrong (University of Manchester)
	Short communications from selected abstracts
16.00-16.15	Macrophage Heterogeneity in Breast Cancer Metastasis - Bin-Zhi Qian (University of Edinburgh)
16.15-16.30	Tumour- and Microenvironment derived IL-1B; interplay in metastatic breast cancer - Claudia Tulotta (University of Sheffield)
16.30-18.30	**Poster session 1, drinks and nibbles**
	Evening program **Chaired by: Ingunn Holen (University of Sheffield)**
18.30-18.45	What a BACR travel exchange can do for your career - Penny Ottewell (University of Sheffield)
18.45-19.00	How to succeed **without** a fellowship – Amanda Harvey (Brunel University)
19.00-19.15	How to involve patients in your research –Lesley Turner (Independent Cancer Patient Voice)
19.15-19.30	Getting patient material for your research – Will Brackenbury, BCNTB success story (University of York)

Day 2

Session 3	**New strategies for treatment of breast cancer – CDK4/6 and PARP inhibitors and beyond** **Chaired by: Lewis Chodosh (University of Pennsylvania, USA)**
9.00-9.30	The science that paved the way for PARP inhibitors - Helen Bryant (University of Sheffield)
9.30-10.00	Inhibiting cyclin-dependent kinases in breast cancer - CDK4/6 inhibitors and beyond - Simak Ali (Imperial College London)
	Short communication from selected abstracts
10.00-10.15	STAT3 signalling in ER+ breast cancer drives anti-estrogen resistance and can be targeted by SFX-01, a novel stabilised formulation of sulforaphane - Bruno Simoes (University of Manchester)
10.15-10.45	**Coffee break**
Session 4	**Tumour cell dormancy and breast cancer recurrence** **Chaired by: Ingunn Holen (University of Sheffield)**
10.45-11.15	Regulation of tumour cell dormancy – Cyrus Ghajar (Fred Hutch Cancer Research Center, USA)
11.15-11.45	Tumour cell dormancy and breast cancer recurrence – Lewis Chodosh (University of Pennsylvania, USA)
	Short communications from selected abstracts
11.45-12.00	NOTCH signalling regulates bone metastatic stem cell dormancy in ER+ breast cancer - Angelica Santiago-Gomez (University of Manchester)
12.00-13.30	**Lunch and networking**
Session 5	**How do we tackle DCIS? Sponsored by The Pathological Society** **Chaired by: Val Speirs (University of Aberdeen)**
13.30-14.00	DCIS – recent developments in clinical research Elly Sawyer (King's College, London)
14.00-14.30	DCIS – to treat or not to treat?— Jelle Wesseling (Netherlands Cancer Institute, The Netherlands)
	Short communications from selected abstracts
14.30-14.45	Do DCIS associated myoepithelial cells alter the inflammatory microenvironment to promote or restrain DCIS progression to invasion? - Michael Allen (Queen Mary University London)
14.45-15.00	Novel rationale for a more targeted use of endocrine therapy in the treatment of ductal carcinoma in situ of the breast (DCIS) - Carlos Martinez-Perez (University of Edinburgh)
15.00-15.30	**Coffee break**
Session 6	**Metabolomics and the microbiome - role in tumour progression and treatment** **Chaired by: Dylan Edwards (University of East Anglia)**
15.30-16.00	Metabolomics – role in tumour progression and therapeutic response– Sarah Maria Fendt (VIB-KU Leuven Center for Cancer Biology, Belgium)
16.00-16.30	The microbiome in breast cancer – friend or foe? – Stephen Robinson (University of East Anglia)
	Short communications from selected abstracts
16.30-16.45	Rac1b: A novel therapeutic target to eradicate breast cancer stem cells in luminal breast tumours - Ahmet Ucar (University of Manchester)
16.45-17.00	Signalling to chromatin in a HER2 inducible and heterogeneous overexpression system - Ateequllah Hayat (Queen Mary University London)
17.00-19.00	**Poster session 2**
	Conference Dinner

Day 3

Session 7	**Computational biology and artificial intelligence** **Chaired by: James Flanagan (Imperial College London)**
9.00-9.30	Mathematical Oncology – what it is and what it can do for you - Alexander Anderson (Moffitt Cancer Center, USA)
9.30-10.00	Artificial Intelligence – use in breast cancer screening and beyond - Hutan Ashrafian (Imperial College London)
	Short communication from selected abstracts
10.00-10.15	Molecular analysis of paired primary and lymph node metastasis breast cancer samples - Andy Sims (University of Edinburgh)
10.15-10.45	**Coffee break**
Session 8	**On the horizon – the next decade** **Chaired by: Val Speirs (University of Aberdeen) and James Flanagan (Imperial College London)**
10.45-11.15	On the horizon – Jo Morris (University of Birmingham)
11.15-11.45	Why we should invest in breast cancer prevention – Gareth Evans (University of Manchester)
11.45-11.55	Closing Remarks - Sharon Hodgson, MP for Washington and Sunderland West
11.55-12.00	**Prizes, Thank You's and Departure**